Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Versiti Diagnostic Laboratories, |
RCV001093531 | SCV001250579 | pathogenic | Von Willebrand disease type 2A | 2019-08-29 | criteria provided, single submitter | clinical testing | The missense variant VWF c.3538G>A, p.Gly1180Arg (p.G1180R) in exon 26 changes amino acid glycine at codon 1180 to arginine. The glycine at this residue is fairly well conserved among species. This amino acid change occurs in the TIL3 domain (Springer, 2014). Pathogenic variants in VWF are associated with autosomal dominant or autosomal recessive von Willebrand disease (VWD), characterized by quantitative or qualitative deficiencies in von Willebrand factor and resulting in prolonged bleeding. This sequence variant has been previously reported in two patients from one family with type 2A VWD where the variant segregated with disease (James, 2004) and has been observed in additional patients with type 2A VWD in our research cohort. To date, this variant has not been reported in the general population (GnomAD, Exome Variant Server, ExAC, Variation Viewer). mRNA analysis of patient platelets and blood outgrowth endothelial cells (BOECs) showed expression of wild-type transcript that did not carry p.G1180R variant as well as transcripts with exon 26 skipping only, transcripts with exons 23 and 26 skipping, and (in BOECs only) transcripts with exon 23 skipping only (James, 2004; Hawke, 2016). Functional studies in mammalian cells of recombinant VWF with exons 23, 26, or 23 & 26 deleted showed significantly reduced VWF secretion caused by intracellular retention, and impaired multimerization resulting in only lowest weight multimers; recombinant VWF mutants demonstrated negligible binding to platelets, factor VIII, or collagen when expressed alone, and marginal to full restoration of binding upon co-expression with wt VWF (James, 2004; Hawke, 2016). Multiple lines of in silico computational evidence (Condel, Polyphen2, Mutation Taster, SIFT, HSF) predict the variant to be damaging; however, the accuracy of these tools is unknown. In summary, the collective evidence supports VWF c.3538G>A, p.Gly1180Arg as a dominant pathogenic variant for type 2A von Willebrand disease. |
| Molecular Diagnostics Laboratory, |
RCV003126497 | SCV003802710 | likely pathogenic | Hereditary von Willebrand disease | 2023-01-05 | criteria provided, single submitter | clinical testing | |
| Academic Unit of Haematology, |
RCV000086663 | SCV000118867 | not provided | not provided | no assertion provided | not provided |